Trial Profile
Second line therapy with Docetaxel + lanreotide in patients with hormone refractory metastatic prostate cancer and progression during chemotherapy of the line with docetaxel. Phase II study.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2014
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms RESTORE
- 26 Sep 2012 New trial record